Trial Profile
A Randomized, Double-Blind, Valsartan-Referenced, Parallel Grouped, Therapeutic Exploratory Clinical Study to Evaluate the Antihypertensive Efficacy of Fimasartan(BR-A-657K) During 24hours by Dose in Patients With Mild to Moderate Essential Hypertension.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Fimasartan (Primary) ; Valsartan
- Indications Essential hypertension
- Focus Therapeutic Use
- Sponsors Boryung Pharmaceutical
- 07 Aug 2013 Results published in Clinical Therapeutics.
- 09 Oct 2009 Actual end date (Aug 2009) added as reported by ClinicalTrials.gov.
- 09 Oct 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.